Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: IRWIN JAMES FRANKEL who wrote (2016)	2/14/2002 1:18:09 PM
From: Cacaito	Read Replies (2) of 2515

Case is building up: ""He said ImClone failed to inform Merck in advance of the FDA's rejection, in breach of their agreement, but the company doesn't intend to take legal action yet. "We are worried that the whole mess will have a negative impact on the product getting to market as soon as possible," Scheuble said. Merck sold most of its 3% stake in ImClone via a tender offer and on the stock market late December, he said. "" From detroit4444 yahoo post part 2 of 2. MerckKA sold 3% stake, this # of shares prices from tender (BMY tender?) $70, to mid $60s - mid $50s in December in open markets (guess aproximate) if at average of $60 they got $ millions

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next